Even after the tremendous victory won by the American Lithotripsy Society and the Urology Society of America last year in federal court, urologists still must be concerned with Stark II and the federal anti-kickback statute.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.